Carlotta Marianecci
Overview
Explore the profile of Carlotta Marianecci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
801
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maurizi L, Lasalvia A, Fabiano M, DIntino E, Del Cioppo F, Fraschetti C, et al.
Pharmaceutics
. 2024 Jul;
16(7).
PMID: 39065624
Most clinical isolates of both and show the capacity to adhere to abiotic surfaces and to develop biofilms resulting in a contribution to chronic human skin infections. Antibiotic resistance and...
2.
Forte J, Fabiano M, Ammendolia M, Puglisi R, Rinaldi F, Ricci C, et al.
Int J Pharm
. 2024 Jul;
661:124380.
PMID: 38950661
Melanoma is an aggressive form of skin cancer with elevated propensity to metastasize. One of the major critical issues in the treatment of oncological patients is represented by the development...
3.
Forte J, Maurizi L, Fabiano M, Conte A, Conte M, Ammendolia M, et al.
Sci Rep
. 2024 May;
14(1):10196.
PMID: 38702355
Urinary tract infections (UTIs) are the most common bacterial infections and uropathogenic Escherichia coli (UPEC) is the main etiological agent of UTIs. UPEC can persist in bladder cells protected by...
4.
Giuli M, Hanieh P, Forte J, Fabiano M, Mancusi A, Natiello B, et al.
Int J Pharm
. 2023 Dec;
649:123672.
PMID: 38052280
The peptidyl-prolyl cis/trans isomerase Pin1 positively regulates numerous cancer-driving pathways, and it is overexpressed in several malignancies, including high-grade serous ovarian cancer (HGSOC). The findings that all-trans retinoic acid (ATRA)...
5.
Forte J, Hanieh P, Poerio N, Olimpieri T, Ammendolia M, Fraziano M, et al.
Biomolecules
. 2023 Jun;
13(6).
PMID: 37371504
(Mabs) is a dangerous non-tubercular mycobacterium responsible for severe pulmonary infections in immunologically vulnerable patients, due to its wide resistance to many different antibiotics which make its therapeutic management extremely...
6.
Rinaldi F, Hanieh P, Maurizi L, Longhi C, Uccelletti D, Schifano E, et al.
Int J Nanomedicine
. 2022 Dec;
17:6447-6465.
PMID: 36573206
Purpose: Vitamin E (VitE) may be classified in "the first line of defense" against the formation of reactive oxygen species. Its inclusion in nanoemulsions (NEs) is a promising alternative to...
7.
Maurizi L, Forte J, Ammendolia M, Hanieh P, Conte A, Relucenti M, et al.
Pharmaceutics
. 2022 Dec;
14(12).
PMID: 36559155
Infections caused by bacterial biofilms represent a global health problem, causing considerable patient morbidity and mortality in addition to an economic burden. , and other medically relevant bacterial strains colonize...
8.
Dri D, Rinaldi F, Carafa M, Marianecci C
Drug Deliv Transl Res
. 2022 Nov;
13(3):757-769.
PMID: 36450964
Elucidation of physical-chemical characteristics of investigational medicinal products should be established with suitable methodology. Characterization of nanomedicines and nanocarriers in clinical trials may require the definition of additional specific properties...
9.
Hanieh P, Ricci C, Bettucci A, Marotta R, Moran C, Cantu L, et al.
Nanomedicine
. 2022 Oct;
46:102611.
PMID: 36228995
Nanoscale echogenic bubbles (NBs), can be used as a theranostic platform for the localized delivery of encapsulated drugs. However, the generation of NBs is challenging, because they have lifetimes as...
10.
Dri D, Gaucci E, Torrieri I, Carafa M, Marianecci C, Gramaglia D
Pharmaceutics
. 2022 Jul;
14(7).
PMID: 35890333
Investigational medicinal products submitted over the course of 3 years and authorized at the Clinical Trials Office of the Italian Medicines Agency as part of a request for authorization of...